Is Enfortumab available on the market in China?

Enfortumab vedotin has not yet obtained marketing approval in China. Urothelial carcinoma is a relatively rare but serious cancer type, and ennozumab is regarded as a potential targeted therapy that can provide a new option for the treatment of this disease.

However, despite some progress and recognition internationally, in China, ennozumab has not yet passed the approval process of the National Medical Products Administration (NMPA) and therefore has not yet received marketing authorization. This means that currently in China, patients cannot obtain ennosumab for treatment through formal channels. There are only enromonumab original drugs abroad, mainly Japanese original drugs, which cost more than 10,000 yuan and are relatively expensive.

This is frustrating news for patients who need this medication. Due to the characteristics of urothelial cancer and the urgency of treatment, these patients need to seek other treatment options or may need to consider purchasing ennozumab through overseas channels. However, purchasing drugs across borders may face many uncertainties and challenges, including issues with price, import procedures, legality, etc.

For many patients and medical experts, the domestic launch of ennozumab is critical to improving the treatment of patients with urothelial cancer. It represents a new and promising treatment option that promises to improve patient survival and quality of life. Therefore, it is hoped that relevant government departments and pharmaceutical companies can speed up the approval process, obtain marketing authorization for ennosumab in China as soon as possible, and include it in the scope of medical insurance reimbursement, so that more patients can benefit from this important treatment drug.

Although ennosumab is not yet available in China, international clinical research and clinical trials are continuing to further evaluate its efficacy and safety in the treatment of urothelial cancer. For patients, participating in clinical trials may be a way to obtain drug treatment, while also helping to promote the launch of this drug in China.